Latest news
VERU: PLATEAU trial enrollment completed, interim data due Q1 2027, and patent protection extended to 2044 - TradingViewTradingView · Mon, 10 Aug 2026 13:21:10 GMTVERU INC. 3Q 2026: Revenue $0 Net loss $6.99M, EPS ($0.3) — 10-Q Summary - TradingViewTradingView · Mon, 10 Aug 2026 13:01:01 GMTVERU: PLATEAU trial fully enrolled; cash supports operations past interim data; key patent secured - TradingViewTradingView · Mon, 10 Aug 2026 12:55:19 GMTVERU: Net loss narrowed, cash increased, but going concern risk remains amid clinical trial progress - TradingViewTradingView · Mon, 10 Aug 2026 12:52:35 GMTVeru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled - TradingViewTradingView · Mon, 10 Aug 2026 11:03:01 GMTVERU: PLATEAU trial fully enrolled; Q3 net loss narrows and patent protection extended to 2044 - TradingViewTradingView · Mon, 10 Aug 2026 10:36:50 GMTVERU Q3'26 Earnings: EPS estimate is (0.32) USD - TradingViewTradingView · Fri, 07 Aug 2026 11:00:32 GMTPrice to book forward of Veru Inc. – NASDAQ:VERU - TradingViewTradingView · Sat, 01 Aug 2026 06:11:27 GMT